- Encouraging clinical data reported from Phase 1/2 trial of sepofarsen for LCA10
- Initial clinical data from Phase 1/2 trial of QR-421a for Usher syndrome type 2 on track for Q1 2020
- QR-1123 Investigational New Drug application active for autosomal dominant retinitis pigmentosa
- €49.3 million net proceeds from public offering extends cash runway into 2022
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. PRQR (the "Company"), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced results for the third quarter of 2019.
"During the third quarter we made great progress towards our mission to bring novel RNA therapies to patients and we recently strengthened our capital position," said Daniel A. de Boer, chief executive officer of ProQR. "In October we announced that LCA10 patients experienced a significant improvement in vision after treatment with sepofarsen in a Phase 1/2 trial. These results strengthen our confidence in the design of the ongoing pivotal Illuminate Phase 2/3 trial and our broader inherited retinal diseases pipeline. The Phase 1/2 trial of QR-421a in Usher syndrome is on track to deliver first clinical data in Q1 2020 and we are about to dose a first patient in a Phase 1/2 trial of QR-1123 for adRP. We strengthened our financial position with a public offering in October that will allow us to fund operations into 2022, well beyond the expected top-line readout of Illuminate."
Corporate Highlights and Business Update
Sepofarsen (QR-110) for Leber's congenital amaurosis 10 (LCA10)
- Presented positive top-line results from the Phase 1/2 clinical trial. In the trial, sepofarsen was observed to be well tolerated with rapid, significant and durable improvements in vision observed at month twelve. The target registration dose for the ongoing Phase 2/3 Illuminate trial showed a favorable benefit/risk profile in the Phase 1/2 trial.
- The top-line results from the Phase 1/2 trial support confidence in the design of the ongoing Phase 2/3 Illuminate trial that could be the sole registration trial for the program. Top-line data from Illuminate are expected during the first half of 2021.
- Received Rare Pediatric Disease designation from the Food and Drug Administration (FDA) for the treatment of LCA10.
QR-421a for Usher syndrome type 2
- The Phase 1/2 Stellar trial of QR-421a in patients with Usher syndrome type 2 is ongoing and on track to deliver interim data during the first quarter of 2020.
QR-1123 for autosomal dominant retinitis pigmentosa (adRP)
- The FDA cleared the Investigational New Drug (IND) application to start a first-in-human clinical trial in patients with adRP. ProQR plans to start enrolling patients in the Phase 1/2 Aurora trial in 2019.
- Received Fast Track designation from the FDA.
Business Updates
- Closed an underwritten public offering of 9,090,909 ordinary shares on October 18, 2019 at a price of $5.50 per share with full exercise of underwriters' option to purchase 1,363,636 additional ordinary shares. Net proceeds totaled approximately €49.3 million. With the addition of this capital ProQR's operations are funded into 2022.
Financial Highlights
At September 30, 2019, prior to the offering on October 18th, ProQR held cash and cash equivalents of €74.8 million, compared to €105.6 million at December 31, 2018. The cash balance at September 30, 2019 excludes the net proceeds of €49.3 million from the underwritten offering of ordinary shares in October 2019. Net cash used in operating activities during the three-month period ended September 30, 2019 was €8.8 million, compared to €4.3 million for the same period last year.
Research and development costs increased to €11.1 million for the quarter ended September 30, 2019 compared to €6.3 million for the same period last year due to increased clinical trial activity.
General and administrative costs increased to €2.9 million for the quarter ended September 30, 2019 compared to €2.6 million for the same period last year.
Net loss for the three-month period ended September 30, 2019 was €12.2 million or €0.31 per share, compared to a €6.0 million loss or €0.18 per share for the same period last year.
In October 2019 the Company sold an aggregate of 10.5 million ordinary shares, with net proceeds to the Company of €49.3 million.
For further financial information for the period ended September 30, 2019, please refer to the financial statements appearing at the end of this release.
About Sepofarsen
Sepofarsen (QR-110) is a first-in-class investigational RNA-based oligonucleotide designed to address the underlying cause of Leber's congenital amaurosis 10 due to the p.Cys998X mutation (also known as the c.2991+1655A>G mutation) in the CEP290 gene. The p.Cys998X mutation leads to aberrant splicing of the mRNA and non-functional CEP290 protein. Sepofarsen is designed to enable normal splicing, resulting in restoration of normal (wild type) CEP290 mRNA and subsequent production of functional CEP290 protein. Sepofarsen is intended to be administered through intravitreal injections in the eye and has been granted orphan drug designation in the United States and the European Union and received fast-track designation and rare pediatric disease designation from the FDA as well as access to the PRIME scheme by the EMA.
About QR-421a
QR-421a is a first-in-class investigational RNA-based oligonucleotide designed to address the underlying cause of vision loss in Usher syndrome type 2 and non-syndromic retinitis pigmentosa (RP) due to mutations in exon 13 of the USH2A gene. QR-421a is designed to restore functional Usherin protein by using an exon skipping approach with the aim to stop or reverse vision loss in patients. QR-421a is intended to be administered through intravitreal injections in the eye and has been granted orphan drug designation in the United States and the European Union and received fast-track designation from the FDA.
About QR-1123
QR-1123 is a first-in-class investigational RNA-based oligonucleotide that was discovered and developed by Ionis Pharmaceuticals using Ionis' proprietary antisense technology for the treatment of adRP due to the P23H mutation in the RHO gene. The therapy aims to inhibit the formation of the mutated toxic version of the rhodopsin protein by specifically binding the mutated RHO mRNA. Binding of QR-1123 causes allele specific knockdown of the mutant mRNA by a mechanism called RNase H mediated cleavage without affecting the normal RHO mRNA. QR-1123 is intended to be administered through intravitreal injections in the eye and received IND clearance in August 2019.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases such as Leber's congenital amaurosis 10, Usher syndrome and autosomal dominant retinitis pigmentosa. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
*Since 2012*
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding sepofarsen (QR-110) and the clinical development and the therapeutic potential thereof, statements regarding our pipeline of programs targeting inherited retinal dystrophies, statements regarding QR-421a, and the clinical development and the therapeutic potential thereof, statements regarding QR-1123 and the clinical development and therapeutic potential thereof, and our financial position and cash runway. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
ProQR Therapeutics N.V.
Investor Contact:
Sarah Kiely
ProQR Therapeutics N.V.
T: +1 617 599 6228
skiely@proqr.com
or
Hans Vitzthum
LifeSci Advisors
T: +1 617 535 7743
hans@lifesciadvisors.com
Media Contact:
Sara Zelkovic
LifeSci Public Relations
T: +1 646 876 4933
sara@lifescipublicrelations.com
PROQR THERAPEUTICS N.V.
Unaudited Condensed Consolidated Statement of Financial Position
| September 30, | December 31, | |||||
| 2019 | 2018 | |||||
| € 1,000 | € 1,000 | |||||
| Assets | ||||||
| Current assets | ||||||
| Cash and cash equivalents | 74,792 | 105,580 | ||||
| Prepayments and other receivables | 2,450 | 1,544 | ||||
| Social securities and other taxes | 830 | 1,243 | ||||
| Total current assets | 78,072 | 108,367 | ||||
| Property, plant and equipment | 2,413 | 1,864 | ||||
| Investments in associates | 579 | — | ||||
| Total assets | 81, 064 | 110,231 | ||||
| Equity and liabilities | ||||||
| Equity | ||||||
| Equity attributable to owners of the Company | 59,871 | 92,915 | ||||
| Non-controlling interests | (452 | ) | (230 | ) | ||
| Total equity | 59,419 | 92,685 | ||||
| Current liabilities | ||||||
| Borrowings | 260 | — | ||||
| Lease liabilities | 890 | — | ||||
| Trade payables | 668 | 135 | ||||
| Social securities and other taxes | 15 | — | ||||
| Pension premiums | 13 | 7 | ||||
| Deferred income | 984 | 545 | ||||
| Other current liabilities | 8,305 | 7,473 | ||||
| Total current liabilities | 11,135 | 8,160 | ||||
| Borrowings | 10,510 | 9,386 | ||||
| Lease liabilities | — | — | ||||
| Total liabilities | 21,645 | 17,546 | ||||
| Total equity and liabilities | 81,064 | 110,231 | ||||
PROQR THERAPEUTICS N.V.
Unaudited Condensed Consolidated Statement of Profit or Loss and OCI
(€ in thousands, except share and per share data)
| Three month period | Nine month period | |||||||||||
| ended September 30, | ended September 30, | |||||||||||
| 2019 | 2018 | 2019 | 2018 | |||||||||
| € 1,000 | € 1,000 | € 1,000 | € 1,000 | |||||||||
| Other income | 530 | 2,958 | 1,509 | 4,428 | ||||||||
| Research and development costs | (11,074 | ) | (6,297 | ) | (32,560 | ) | (19,972 | ) | ||||
| General and administrative costs | (2,903 | ) | (2,579 | ) | (8,970 | ) | (7,900 | ) | ||||
| Total operating costs | (13,977 | ) | (8,876 | ) | (41,530 | ) | (27,872 | ) | ||||
| Operating result | (13,447 | ) | (5,918 | ) | (40,021 | ) | (23,444 | ) | ||||
| Finance income and expense | 1,375 | (74 | ) | 1,339 | (664 | ) | ||||||
| Results related to associates | (119 | ) | — | 579 | — | |||||||
| Result before corporate income taxes | (12,191 | ) | (5,992 | ) | (38,103 | ) | (24,108 | ) | ||||
| Income taxes | — | — | (64 | ) | (1 | ) | ||||||
| Result for the period | (12,191 | ) | (5,992 | ) | (38,167 | ) | (24,109 | ) | ||||
| Other comprehensive income | 147 | (4 | ) | 121 | (15 | ) | ||||||
| Total comprehensive income (attributable to owners of the Company) | (12,044 | ) | (5,996 | ) | (38,046 | ) | (24,124 | ) | ||||
| Result attributable to | ||||||||||||
| Owners of the Company | (12,139 | ) | (5,959 | ) | (37,945 | ) | (23,974 | ) | ||||
| Non-controlling interests | (52 | ) | (33 | ) | (222 | ) | (135 | ) | ||||
| (12,191 | ) | (5,992 | ) | (38,167 | ) | (24,109 | ) | |||||
| Share information | ||||||||||||
| Weighted average number of shares outstanding1 | 38,912,701 | 33,355,327 | 38,902,203 | 32,440,220 | ||||||||
| Earnings per share attributable to the equity holders of the Company (expressed in Euro per share) | ||||||||||||
| Basic loss per share1 | (0.31 | ) | (0.18 | ) | (0.98 | ) | (0.74 | ) | ||||
| Diluted loss per share1 | (0.31 | ) | (0.18 | ) | (0.98 | ) | (0.74 | ) | ||||
1. For this period presented in these financial statements, the potential exercise of share options is not included in the diluted earnings per share calculation as the Company was loss-making in all periods. Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal in this period.
PROQR THERAPEUTICS N.V.
Unaudited Condensed Consolidated Statement of Changes in Equity
| Attributable to owners of the Company | ||||||||||||||||||||||||
| Equity | ||||||||||||||||||||||||
| Settled | ||||||||||||||||||||||||
| Employee | Non- | |||||||||||||||||||||||
| Number of | Share | Share | Benefit | Translation | Accumulated | controlling | Total | |||||||||||||||||
| shares | Capital | Premium | Reserve | Reserve | Deficit | Total | interests | Equity | ||||||||||||||||
| € 1,000 | € 1,000 | € 1,000 | € 1,000 | € 1,000 | € 1,000 | € 1,000 | € 1,000 | |||||||||||||||||
| Balance at January 1, 2018 | 36,425,014 | 1,457 | 148,763 | 8,377 | 136 | (119,370 | ) | 39,363 | (38 | ) | 39,325 | |||||||||||||
| Result for the period | — | — | — | — | — | (23,974 | ) | (23,974 | ) | (135 | ) | (24,109 | ) | |||||||||||
| Other comprehensive income | — | — | — | — | (15 | ) | — | (15 | ) | — | (15 | ) | ||||||||||||
| Recognition of share-based payments | — | — | — | 2,245 | — | — | 2,245 | — | 2,245 | |||||||||||||||
| Issuance of ordinary shares | 6,612,500 | 265 | 84,032 | — | — | — | 84,297 | — | 84,297 | |||||||||||||||
| Share options exercised | — | — | 659 | — | — | — | 659 | — | 659 | |||||||||||||||
| Balance at September 30, 2018 | 43,037,514 | 1,722 | 233,454 | 10,622 | 121 | (143,344 | ) | 102,575 | (173 | ) | 102,402 | |||||||||||||
| Balance at January 1, 2019 | 43,149,987 | 1,726 | 235,744 | 10,780 | 108 | (155,443 | ) | 92,915 | (230 | ) | 92,685 | |||||||||||||
| Result for the period | — | — | — | — | — | (37,945 | ) | (37,945 | ) | (222 | ) | (38,167 | ) | |||||||||||
| Other comprehensive income | — | — | — | — | 121 | — | 121 | — | 121 | |||||||||||||||
| Recognition of share-based payments | — | — | — | 4,614 | — | — | 4,614 | — | 4,614 | |||||||||||||||
| Share options lapsed | — | — | — | (33 | ) | 33 | — | — | — | |||||||||||||||
| Share options exercised | — | — | 166 | (115 | ) | — | 115 | 166 | — | 166 | ||||||||||||||
| Balance at September 30, 2019 | 43,149,987 | 1,726 | 235,910 | 15,246 | 229 | (193,240 | ) | 59,871 | (452 | ) | 59,419 | |||||||||||||
PROQR THERAPEUTICS N.V.
Unaudited Condensed Consolidated Statement of Cash Flows
| Three month period | Nine month period | |||||||||||
| ended September 30, | ended September 30, | |||||||||||
| 2019 | 2018 | 2019 | 2018 | |||||||||
| € 1,000 | € 1,000 | € 1,000 | € 1,000 | |||||||||
| Cash flows from operating activities | ||||||||||||
| Net result | (12,191 | ) | (5,992 | ) | (38,167 | ) | (24,109 | ) | ||||
| Adjustments for: | ||||||||||||
| — Depreciation | 506 | 242 | 1,543 | 725 | ||||||||
| — Share-based compensation | 1,226 | 734 | 4,614 | 2,245 | ||||||||
| — Financial income and expenses | (1,375 | ) | 74 | (1,339 | ) | 664 | ||||||
| — Results related to associates | 119 | — | (579 | ) | — | |||||||
| — Net foreign exchange gain / (loss) | 148 | (4 | ) | 122 | (15 | ) | ||||||
| Changes in working capital | 2,718 | 656 | 1,744 | 1,074 | ||||||||
| Cash used in operations | (8,849 | ) | (4,290 | ) | (32,062 | ) | (19,416 | ) | ||||
| Corporate income tax paid | — | 1 | (64 | ) | — | |||||||
| Interest received | 90 | 32 | 176 | 25 | ||||||||
| Interest paid | (13 | ) | — | (64 | ) | — | ||||||
| Net cash used in operating activities | (8,772 | ) | (4,257 | ) | (32,014 | ) | (19,391 | ) | ||||
| Cash flow from investing activities | ||||||||||||
| Purchases of intangible assets | — | — | — | — | ||||||||
| Purchases of property, plant and equipment | (32 | ) | (99 | ) | (341 | ) | (285 | ) | ||||
| Net cash used in investing activities | (32 | ) | (99 | ) | (341 | ) | (285 | ) | ||||
| Cash flow from financing activities | ||||||||||||
| Proceeds from issuance of shares, net of transaction costs | — | 84,295 | — | 84,295 | ||||||||
| Proceeds from exercise of share options | 2 | 637 | 166 | 660 | ||||||||
| Proceeds from borrowings | — | — | — | 101 | ||||||||
| Proceeds from convertible loans | — | 115 | 690 | 430 | ||||||||
| Repayment of lease liability | (290 | ) | — | (861 | ) | — | ||||||
| Net cash (used in)/generated by financing activities | (288 | ) | 85,047 | (5 | ) | 85,486 | ||||||
| Net increase/(decrease) in cash and cash equivalents | (9,092 | ) | 80,691 | (32,360 | ) | 65,810 | ||||||
| Currency effect cash and cash equivalents | 1,420 | 57 | 1,572 | (193 | ) | |||||||
| Cash and cash equivalents, at beginning of the period | 82,464 | 32,968 | 105,580 | 48,099 | ||||||||
| Cash and cash equivalents at the end of the period | 74,792 | 113,716 | 74,792 | 113,716 | ||||||||
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
